drugset
drugset / Trial / NCT00050986

Phase I/II Evaluation of Temozolomide and ZARNESTRA (R115777) for Recurrent and Progressive Glioblastoma Multiforme

NCT00050986 ↗

Phase 1/2 Completed 55 enrolled M.D. Anderson Cancer Center Johnson & Johnson · collab
NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to find the highest safe dose of the new drug ZARNESTRA (R115777) and temozolomide that can be given to patients with brain tumors (glioblastoma multiforme, GBM). The second goal is to learn if these drugs given in combination can shrink or slow the growth of brain tumors. The safety of this treatment will also be studied.

Timeline

Start
2002-12
Primary completion
2008-10
Completion
2008-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Temozolomide Small molecule 100 mg/m2 Oral
Subject tipifarnib Small molecule 400 mg Oral

Indications

glioblastoma